Comparative Pharmacology
Head-to-head clinical analysis: ALYQ versus IMPOYZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYQ versus IMPOYZ.
ALYQ vs IMPOYZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Category C
Category C
Unknown
Unknown